Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Livmoniplimab + budigalimab plus platinum-doublet chemotherapy versus pembrolizumab plus platinum-doublet chemotherapy in untreated metastatic non-squamous NSCLC
NL-OMON59585Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Non-small cell lung cancer (NS-NSCLC) comparing Livmoniplimab + budigalimab + platinum-doublet chemotherapy with Pembrolizumab + platinum-doublet chemotherapy (2 arms). Primary endpoints: Best overall response of complete response or partial response and Overall survival. Started Apr 2025; status: active, not recruiting.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on NL-OMON59585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59585.